

VITILIGO

Picardo, Mauro; Taïeb, Alain (Eds.)

Vitiligo is one of the most common cutaneous disorders. Great numbers of affected patients suffer from the high stigmatizing impact of this disease. Up to now, clinical guidelines for the treatment of vitiligo were non-existent. In order to fill this void, this textbook defines and gives a complete overview of the disease, both regarding the classification of differential diagnosis as well as the treatment. Written by the most authoritative experts in the field, all therapy recommendations are based on new evidence-based guidelines. It includes case studies with illustrations before and after the treatment in order to demonstrate the treatment success. This textbook will be a valuable resource for all physicians who are seeing patients with this disease.

- First highly up-to-date book showing new therapies for vitiligo
- Is lavishly illustrated, covering all aspects
- Presents an overview on the classification, pathogenesis, methods of diagnosis and treatment of vitiligo
- All therapy recommendations are based on new evidence-based guidelines
- Includes case studies with illustrations before and after the treatment, demonstrating treatment success
- Is designed for beginners in the field as well as experts

TABLE OF CONTENTS

Section 1: Defining the Disease

| | |
|--|----|
| 1.1 Historical Aspects | 3 |
| Yvon Gauthier and Laila Benzekri | |
| 1.2 Clinical Overview | 11 |
| 1.2.1 Epidemiology, Definitions and Classification | 13 |
| Alain Taïeb and Mauro Picardo | |
| 1.2.2 Histopathology | 25 |
| Flávia Pretti Aslanian, Absalom Figueira, Tullia Cuzzi, and Béatrice Vergier | |
| 1.3 Clinical Aspects | 33 |
| 1.3.1 Generalized Vitiligo | 35 |
| Thierry Passeron and Jean-Paul Ortonne | |
| 1.3.2 Segmental Vitiligo | 41 |
| Seung-Kyung Hann, Yvon Gauthier, and Laila Benzekri | |
| 1.3.3 Vitiligo Universalis | 51 |
| Prasad Kumarasinghe. | |
| 1.3.4 Mucosal Vitiligo | 57 |
| Davinder Parsad | |
| 1.3.5 Halo Nevi and Vitiligo | 61 |
| Thomas Jouary and Alain Taïeb | |
| 1.3.6 Hair Involvement in Vitiligo | 65 |
| Rafael Falabella | |
| 1.3.7 Non-Skin Melanocytes in Vitiligo | 73 |
| Raymond E. Boissy | |
| 1.3.8 Autoimmune/Inflammatory and Other Diseases Associated with Vitiligo | 79 |
| Ilse Mollet, Nanny van Geel, and Jo Lambert | |
| 1.3.9 Vitiligo and Immunodeficiencies | 91 |
| Khaled Ezzedine, Sébastien Lepreux, and Alain Taïeb | |

| | |
|--|-----|
| 1.3.10 Inflammatory Vitiligo | 99 |
| Khaled Ezzedine, Julien Seneschal, Ratnam Attili, and Alain Taïeb | |
| 1.3.11 Rare Inherited Diseases and Vitiligo | 107 |
| Alain Taïeb and Fanny Morice-Picard | |
| 1.3.12 Vitiligo in Childhood | 117 |
| Juliette Mazereeuw-Hautier and Alain Taïeb | |
| 1.3.13 Late-Onset Vitiligo | 123 |
| Davinder Parsad and Dipankar D | |
| 1.4 Evaluation, Assessment and Scoring | 127 |
| Alain Taïeb and Mauro Picardo | |
| 1.5 Quality of Life | 135 |
| Davinder Parsad | |
| 1.6 Natural History and Prognosis | 139 |
| Davinder Parsad | |
| 1.7 Defining the Disease: Editor’s Synthesis | 143 |
| Alain Taïeb and Mauro Picardo | |
| Section 2: Understanding the Disease | |
| 2.1 Pathophysiology Overview | 149 |
| Mauro Picardo and Alain Taïeb | |
| 2.2 Generalized Vitiligo | 153 |
| 2.2.1 Genetics | 155 |
| Richard Spritz | |
| 2.2.2 Environmental Factors | 165 |
| 2.2.2.1 The Kobner’s Phenomenon | 167 |
| Yvon Gauthier and Laila Benzekri | |
| 2.2.2.2 Occupational Vitiligo | 175 |
| Raymond E. Boissy | |
| 2.2.3 In Vivo Data | 181 |
| 2.2.3.1 Non-Invasive Methods for Vitiligo Evaluation | 183 |
| Marco Ardigò, Francesca Muzio, Mauro Picardo, and Valeria Brazzelli | |
| 2.2.3.2 Electron Microscopy | 197 |
| Yvon Gauthier | |
| 2.2.4 Animal Models | 205 |
| Gisela F. Erf. | |
| 2.2.5 In Vitro Approaches | 219 |
| Muriel Cario-André and Maria Lucia Dell’Anna | |
| 2.2.6 Oxidative Stress | 231 |
| Mauro Picardo and Maria Lucia Dell’Anna | |
| 2.2.7 Immune/Inflammatory Aspects | 239 |
| 2.2.7.1 Introduction | 239 |
| Alain Taïeb | |
| 2.2.7.2 The Role of Innate Immunity in Vitiligo | 240 |
| Anna Peroni and Giampiero Girolomoni | |
| 2.2.7.3 Humoral Immunity | 248 |
| E. Helen Kemp, Anthony P. Weetman, and David J. Gawkrödger | |
| 2.2.7.4 Cell-Mediated Immunity | 256 |
| I. Caroline Le Poole and David A. Norris | |
| 2.2.8 Cytokines and Growth Factors | 269 |
| Genji Imokawa and Silvia Moretti | |
| 2.2.9 Proopiomelanocortin and Related Hormones | 283 |
| Markus Böhm | |
| 2.2.10 Other Hypotheses | 291 |
| Mauro Picardo | |

| | |
|---|-----|
| 2.3 Segmental Vitiligo: A Model to Understand Vitiligo? | 295 |
| 2.3.1 Particular Clinical Characteristics of Segmental Vitiligo | 296 |
| Seung-Kyung Hann | |
| 2.3.2 The Concept of Mosaicism Applied to SV | 298 |
| Alain Taïeb.. | |
| 2.3.3 The Neurogenic Hypothesis in Segmental Vitiligo | 302 |
| Yvon Gauthier and Laila Benzekri | |
| 2.3.4 Segmental Vitiligo: A Model for Understanding the Recapitulation of Repigmentation | 306 |
| Hsin-Su Yu, Cheng-Che Eric Lan, and Ching-Shuang Wu | |
| 2.4 Editor's Synthesis | 311 |
| Mauro Picardo and Alain Taïeb | |
| Section 3: Therapy | |
| 3.1 Management Overview | 319 |
| Alain Taïeb and Mauro Picardo | |
| 3.2 Topical Therapies | 325 |
| 3.2.1 Topical Corticosteroids | 327 |
| Wietze Van der Veen, Bas S. Wind, and Alain Taïeb | |
| 3.2.2 Calcineurin Inhibitors | 331 |
| N. van Geel, B. Boone, I. Mollet, and J. Lambert | |
| 3.2.3 Vitamin D Analogues | 339 |
| Mauro Picardo. | |
| 3.3 Phototherapies | 343 |
| 3.3.1 PUVA and Related Treatments | 345 |
| Agustin Alomar | |
| 3.3.2 UVB Total Body and Targeted Phototherapies | 353 |
| Giovanni Leone and Adrian Tanew | |
| Microphototherapy | 362 |
| Torello Lotti, Francesca Prignano, and Gionata Buggiani | |
| 3.4 Vitamins and Antioxidants: Topical and Systemic. | 369 |
| Mauro Picardo and Maria Lucia Dell'Anna | |
| 3.5 Systemic Treatments | 375 |
| 3.5.1 Corticosteroid Minipulses | 377 |
| Davinder Parsad and Dipankar De | |
| 3.5.2 Other Immunosuppressive Regimen | 381 |
| Markus Böhm | |
| 3.6 Empirical, Traditional, and Alternative Treatments. | 387 |
| Mauro Picardo and Alain Taïeb | |
| 3.7 Surgical Therapies | 393 |
| 3.7.1 Background and Techniques | 395 |
| Mats J. Olsson | |
| 3.7.2 The Outcomes: Lessons About Surgical Therapy for Vitiligo in the Past Two Decades. | 409 |
| Rafael Falabella | |
| 3.8 Combined Therapies for Vitiligo. | 417 |
| Thierry Passeron and Jean-Paul Ortonne | |
| 3.9 Camouflage | 423 |
| Alida de Pase and Thomas Jouary | |
| 3.10 Photoprotection Issues | 431 |
| Alessia Pacifico, Giovanni Leone and Mauro Picardo | |
| 3.11 Depigmenting Agents | 439 |
| Mauro Picardo and Maria Lucia Dell'Anna | |
| 3.12 Therapy Adapted for Age, Gender, and Specific Locations | 443 |
| Alain Taïeb and Inka Nieuweboer-Krobotova. | |
| 3.13 Psychological Interventions | 447 |
| Panagiota Kostopoulou and Alain Taïeb | |

| | |
|--|-----|
| 3.14 The Patient Perspective | 451 |
| Maxine E. Whitton and Alida DePase | |
| 3.15 Evidence-Based Medicine Perspective | 461 |
| Jean-Paul Ortonne, Thierry Passeron, DJ Gawkrödger, Davinder Prasad, and Somesh Gupta | |
| 3.16 Editor's Synthesis and Perspectives | 471 |
| Alain Taieb and Mauro Picardo | |

PREFACE

Vitiligo has been, until recently, a rather neglected area in dermatology and medicine. Patients complain about this situation, which has offered avenues to quacks, and has led to the near orphan status of the disease. The apparently, simple and poorly symptomatic presentation of the disease has been a strong disadvantage to its study, as compared to other common chronic skin disorders such as psoriasis and atopic dermatitis. Vitiligo is still considered by doctors as a non disease, a simple aesthetic problem. A good skin-based angle of attack is also lacking because generalized vitiligo is clearly epitomizing the view of skin diseases as simple targets of a systemic unknown dysregulation (diathesis), reflecting the Hippocratic doctrine. This view has mostly restricted vitiligo to the manifestation of an auto-immune diathesis in the past 30 years. Thus, skin events, which are easily detected using skin biopsies in most other situations, have not been precisely recorded, with the argument that a clinical diagnosis was sufficient for the management (or most commonly absence of management) of the patient.

This book is an international effort to summarize the information gathered about this disorder at the clinical, pathophysiological and therapeutic levels. Its primary aim is to bridge current knowledge at the clinical and investigative level, to point to the many unsolved issues, and to delineate future priorities for research. Its impetus was also to provide the best guidelines for integrated patient care, which is currently possible at a very limited number of places around the world, especially for surgical procedures.

A striking feature in the vitiligo field was, until recently, the absence of consensus on definitions, nomenclature, and outcome measures. With a group of European dermatologists, who had a strong interest in vitiligo and pigment cell research, we had launched some years ago, the Vitiligo European Task Force (VETF). The VETF has addressed those issues as a priority. This group, joined by other colleagues from the rest of the world also involved in the vitiligo research community, has communicated its experience in this book. We have tried to pilot the editing of the book according to consistent principles based on discussions held at VETF meetings and international IPCC (international pigment cell conference) workshops. However, some areas remain controversial and we have highlighted the existing conflicting issues and uncertainties.

After reviewing the field, much needs to be done. In particular, besides basic research based on the many hypotheses raised, new unbiased epidemiological, clinical, histopathological, natural history, and therapeutic data are clearly needed. They should be confronted by genetics and other investigative variables to better define the disease and its subsets. We hope that the combined efforts of all participating authors will prove useful to bring more attention to this field, and we are confident that both the research community (the mystery of melanocyte loss in vitiligo is a true scientific challenge) and the drug industry (the potential market is large) will be stimulated to bring in new treatment strategies to this large number of patients with unmet needs.

Alain Taieb Bordeaux, France
Mauro Picardo Rome, Italy